This page shows the latest Rotarix news and features for those working in and with pharma, biotech and healthcare.
If approved the drug is anticipated to surpass sales of GSK’s Rotarix vaccine. ... Market observers have suggested that - if approved - the vaccine could meet or even exceed sales of GSK's Rotarix vaccine for rotavirus-related diarrhoea, which was
GSK committed to a 10-year price freeze for Synflorix - currently selling at $3.40 per dose - as well as other vaccines provided to GAVI including rotavirus vaccine Rotarix and the
The study - conducted by Sanofi affiliate Shantha Biotechnics - aims to show that the live-attenuated vaccine candidate is at least as good as currently-licensed vaccines such as GlaxoSmithKline's Rotarix ... III trials, promising to make it available at
GSK has an existing relationship with GAVI, and has agreements in place to provide rotavirus vaccine Rotarix and pneumococcal polysaccharide conjugate vaccine Synflorix to the Alliance at reduced prices for use
GSK has offered its rotavirus vaccine Rotarix to the GAVI Alliance at a reduced price following a UNICEF request. ... GSK has made a new offer to supply its rotavirus vaccine Rotarix to the GAVI Alliance at $2.50 per dose, in response to a UNICEF request.
Sales in the US were impacted by individual factors and adverse prior year comparisons, such as an acceleration of generic competition to Valtrex (valacyclovir), the temporary suspension of Rotarix (rotavirus vaccine),
More from news
Approximately 1 fully matching, plus 22 partially matching documents found.
In this role he headed the global commercial teams of GSK and was responsible for the development and implementation of the launch strategy for several drugs, including Rotarix, Priorix and Varilix.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...